Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.
Kirk Campbell, MD
Advertisement
Kirk Campbell, MD, is chief of the renal division at the University of Pennsylvania and the current president of the National Kidney Foundation.
Articles by Kirk Campbell, MD
Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
3
ACA Enrollment Erosion Deepens After Open Enrollment Ends
4
Efgartigimod Effective in Broad Subsets of Patients With gMG
5